Lotus Pharmaceutical announced today that its Board of Directors has approved a capital increase of US$20 million for its wholly-owned Singapore subsidiary, Lotus International Pte. Ltd.
The company stated that this investment is intended to optimize its product portfolio and strengthen the subsidiary's working capital.
Founded in 1966, Lotus Pharmaceutical operates as a global pharmaceutical company. Leveraging its integrated research, development, and manufacturing platforms, the company has established strategic partnerships across major international markets, including the United States, Europe, Japan, China, and Brazil.
FACT BOX
- Source: CNA (Central News Agency)
- Category: business/finance